original ) (raw )Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial
Cristian Cotrutz
International Journal of Radiation Oncology Biology Physics, 2009
View PDFchevron_right
Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy
Chandana Reddy
Cancer, 2004
View PDFchevron_right
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer
Harcharan Gill
2012
View PDFchevron_right
Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer
Clair Beard
Urology, 2005
View PDFchevron_right
Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol
Lucas Mendez
Frontiers in Oncology
View PDFchevron_right
The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer
Marie-Pierre Sylvestre
Cancer Epidemiology
View PDFchevron_right
Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
viola chen
Radiation Oncology, 2013
View PDFchevron_right
Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer
Mack Roach
Practical Radiation Oncology, 2015
View PDFchevron_right
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence
Caio Viani Arruda
2019
View PDFchevron_right
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
Donald Fuller
JAMA Network Open, 2019
View PDFchevron_right
Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer
Leonard Chen
Acta Oncologica, 2015
View PDFchevron_right
SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment
Sergiusz Nawrocki
2019
View PDFchevron_right
Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer
Holger Borchers
Radiotherapy and Oncology, 2010
View PDFchevron_right
Changes in prostate-specific antigen midway through salvage radiotherapy may be associated with long-term outcomes
Harmar Brereton
Journal of Radiation Oncology, 2019
View PDFchevron_right
Prognostic factors for salvage radiotherapy with an analysis of post-prostatectomy PSA kinetics
Sejong Bae
View PDFchevron_right
Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: Preliminary Toxicity Results of a Phase 2 Trial
Donald Fuller
International Journal of Radiation Oncology*Biology*Physics, 2017
View PDFchevron_right
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
viola chen
Radiation Oncology, 2013
View PDFchevron_right
Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: Prognostic value of a time-and-PSA threshold model
chandana reddy
Cancer, 2004
View PDFchevron_right
Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes
Chandana Reddy
International Journal of Radiation Oncology*Biology*Physics, 2016
View PDFchevron_right
Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?
Alexandre Mamedov
Radiotherapy and Oncology, 2017
View PDFchevron_right
Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients
Donald Fuller
International Journal of Radiation Oncology*Biology*Physics, 2021
View PDFchevron_right
Prostate-Specific Antigen Kinetics After Brachytherapy or External Beam Radiotherapy and Neoadjuvant Hormonal Therapy
Holger Borchers
Urology, 2007
View PDFchevron_right
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
Bieke Lambert , Gert De Meerleer , Valérie Fonteyne
Radiation Oncology, 2014
View PDFchevron_right
Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy
Pierre-Yves Bondiau
Radiation oncology (London, England), 2017
View PDFchevron_right
Dose response in prostate cancer with 8-12 years follow-up
Eric Horwitz
International Journal of Radiation Oncology*Biology*Physics, 2001
View PDFchevron_right
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
Najeeb Mohideen
International Journal of Radiation Oncology*Biology*Physics, 2018
View PDFchevron_right
Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
Soehartati Gondhowiardjo
Cancers
View PDFchevron_right